Navigation Links
Aegera Therapeutics welcomes two experienced executives to its board of directors
Date:4/24/2008

MONTREAL, April 24 /PRNewswire/ - Aegera Therapeutics Inc. is very pleased to announce the appointment of two experienced biotechnology and financial executives to its Board of Directors: Mr. Jeremy Curnock Cook, Executive Chairman and Founder of BioScience Managers Limited, and Mr. Gary Littlejohn, Managing Director of Desjardins Securities.

"Gary and Jeremy's extensive industry experience and networks will be critical for Aegera as we make key strategic decisions in support of the attainment of our corporate vision of becoming a profitable, public biotechnology company," commented Mr. James Rae, Chairman of the Board, Aegera Therapeutics Inc.

"I am extremely enthusiastic about joining Aegera's Board at such a critical and exciting time for the company," stated Mr. Curnock Cook. "Their recent clinical and business milestone achievements are very impressive by any measure and I look forward to working with management and the Board to assist the company in accelerating their efforts to achieve their very aggressive business plan."

"Aegera is one of Canada's premier biotechnology companies." added Mr. Littlejohn. "I look forward to working with the accomplished executive team to capitalize on their successes and to continue to build shareholder value both as a private and potentially as a public company."

Mr. Curnock Cook and Mr. Littlejohn join Aegera's existing Board consisting of the following members:

- Mr. James M. Rae, Chairman, President, Remedis Consulting

- Dr. Michael J. Berendt, President & CEO, Aegera Therapeutics

- Dr. Ines Holzbaur, Vice-President, GeneChem Management

- Mr. Serge Langford, Managing Partner, Multiple Capital

- Dr. Luc Marengere, Managing General Partner, Vengrowth Capital

Management

- Mr. Joseph Regan, B.Sc., MBA, Vice President, GrowthWorks Capital

- Mr. Lennie Ryer, B. Comm, CA, CFE, CFO and VP Finance, ConjuChem

The detailed biographies
'/>"/>

SOURCE AEGERA THERAPEUTICS INC.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
2. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
3. CardioVascular BioTherapeutics, Inc. Funding Wound Healing Trial with R&D Partnership
4. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
5. United Therapeutics to Announce First Quarter 2008 Financial Results Before Market Open on Thursday, May 1, 2008
6. ImaRx Therapeutics Satisfies Abbott Note Obligation Associated With the Acquisition of Urokinase
7. Sirion Therapeutics Preclinical Studies: Two New Potential Advances in Treatment of Retinal Diseases to be Presented at ARVO
8. CardioVascular BioTherapeutics, Inc. Announces Update on Timing of Form 10-K Filing
9. Cell Therapeutics, Inc. Announces Receipt of Letter From the NASDAQ Stock Market Regarding Non-Compliance With the Minimum Bid Price Requirement
10. BioSpace and IBC Life Sciences Announce Career Fair Alliance For Drug Discovery & Development of Innovative Therapeutics World Congress
11. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... SAN MARINO, Calif. , May 23, 2013 ... announces today a strategic alliance with DAK Renewable ... increase the corn oil yield. VG Energy is ... Inc. (OTC Pink: VGLS). VG Energy,s ... pathways to increase the oil yield in plants, ...
(Date:5/23/2013)... On April 19th the Center for Disease ... the growing antibiotic resistant bacteria that may be lurking ... study were released late last month showing higher antibiotic ... years. For those suffering from bacteria driven acne, Probiotic ... in food, may eventually help breed acne causing bacteria. ...
(Date:5/23/2013)... Mass. , May 23, 2013 Pressure ... announced that the Company will host a teleconference to ... provide a business update. The teleconference information is provided ... 11:00 a.m. Eastern Daylight Time (EDT) Dial-in: ... ); (302) 607-2001 (Int,l) Passcode: VS22823 For ...
(Date:5/23/2013)... 2013 SynCardia Systems, Inc. ( http://www.syncardia.com ... Health Canada and CE (Europe) approved Total Artificial Heart, ... which boasts more than 380,000 visitors annually, is featuring ... by the Freedom® portable driver as part of its ... exhibitions of its kind. , “BodyWorks combines the ...
Breaking Biology Technology:VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 3Acne Cream, Probiotic Action Shares News on How Some Food may Breed Acne Causing Bacteria 2Pressure BioSciences, Inc. to Discuss First Quarter 2013 Financial Results and Provide Business Update 2SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 2SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 3
... Up 61%, Six-Month Net Revenues Up 40%, ETHEX Corporation Net Revenues Up 102% for Second Quarter ... ... for Six ... Months, ST. LOUIS, Nov. 20 KV Pharmaceutical Company,(NYSE: KVa/KVb) today reported preliminary ...
... PLEASANTON, Calif., Nov. 19 Thoratec,Corporation (Nasdaq: ... treat,cardiovascular disease, today announced the appointment of healthcare,executive ... effective January 1,2008. His appointment brings the Thoratec ... join the board,s compensation and option committee, is,executive ...
... Kline Report on Smart Coatings Cites Immediate Opportunities in ... Coatings, Cool Paint, and Smart Glass -, LITTLE ... and Medicaid that they will no longer reimburse expenses ... the paint and coatings industries to sell antimicrobial coatings,according ...
Cached Biology Technology:KV Pharmaceutical Company Reports Record Revenues for Fiscal 2008 Second Quarter and Six Months on a Preliminary Basis 2KV Pharmaceutical Company Reports Record Revenues for Fiscal 2008 Second Quarter and Six Months on a Preliminary Basis 3KV Pharmaceutical Company Reports Record Revenues for Fiscal 2008 Second Quarter and Six Months on a Preliminary Basis 4KV Pharmaceutical Company Reports Record Revenues for Fiscal 2008 Second Quarter and Six Months on a Preliminary Basis 5KV Pharmaceutical Company Reports Record Revenues for Fiscal 2008 Second Quarter and Six Months on a Preliminary Basis 6KV Pharmaceutical Company Reports Record Revenues for Fiscal 2008 Second Quarter and Six Months on a Preliminary Basis 7KV Pharmaceutical Company Reports Record Revenues for Fiscal 2008 Second Quarter and Six Months on a Preliminary Basis 8KV Pharmaceutical Company Reports Record Revenues for Fiscal 2008 Second Quarter and Six Months on a Preliminary Basis 9KV Pharmaceutical Company Reports Record Revenues for Fiscal 2008 Second Quarter and Six Months on a Preliminary Basis 10Thoratec Announces Appointment of Steven H. Collis to Board of Directors 2Thoratec Announces Appointment of Steven H. Collis to Board of Directors 3Change in Medicare and Medicaid Legislation Creates Market for Antimicrobial Coatings In the U.S. 2
(Date:5/23/2013)... year, carrying more than 284 million tons of cargo, transit ... in toll fees for the Panama Canal Authority. Each time ... water are used from Gatun Lake, which is also a ... the isthmus. , However, the advent of very large ... ships at sea, has demanded change. The Panama Canal is ...
(Date:5/23/2013)... By discovering the new mechanism by which estrogen suppresses ... revealed a potential new approach toward treating certain liver ... and colleagues believe they are changing long-held views in ... issue of the journal Science Signaling . , ... years has been that only receptors located in the ...
(Date:5/23/2013)... the overall health, development, and academic success of ... ensuring that all students have opportunities to engage ... vigorous or moderate-intensity physical activity, says a new ... estimates suggest that only about half of school-age ... health and development. The report recommends that ...
Breaking Biology News(10 mins):Reforestation study shows trade-offs between water, carbon and timber 2Reforestation study shows trade-offs between water, carbon and timber 3UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 3
... 18th. The German research vessel Polarstern, operated by the ... the Helmholtz Association, will begin its 24th Arctic expedition ... nations will research the whole spectrum of current Arctic ... climate development, effects on the ecosystem ranging from bacteria ...
... N.H. University of New Hampshire professor Frederick Short ... the only environmental award of its kind given ... a project that restored eelgrass to coastal salt ponds ... efforts, this award from the p resident recognizes outstanding ...
... in French . For climatologists, part of ... what happened during previous periods of global climate change. ... 33.5 million years ago in the Late Eocene and Early ... falling and the hothouse warmth of the dinosaur age and ...
Cached Biology News:Research vessel Polarstern starts 24th Arctic season 2UNH researcher receives presidential environmental award 2When palm trees gave way to spruce trees 2
Rabbit Anti-JNK1/SAPK pan, Polyclonal Antibody...
...
Low melting point. Ideally suited for in gel enzymatic reactions. Gelling temp. 24-28C Melting temp. 65C. EEO 0.12 Resolution 0.5-20 kb; Rnase/Dnase: none detected....
QPRT Immunogen: QPRT (NP_055113, 198 a.a. ~ 298 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: